Robert Riesenberg

3.9k total citations · 1 hit paper
39 papers, 1.8k citations indexed

About

Robert Riesenberg is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert Riesenberg has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 10 papers in Pharmacology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert Riesenberg's work include Treatment of Major Depression (8 papers), Schizophrenia research and treatment (8 papers) and Maternal Mental Health During Pregnancy and Postpartum (7 papers). Robert Riesenberg is often cited by papers focused on Treatment of Major Depression (8 papers), Schizophrenia research and treatment (8 papers) and Maternal Mental Health During Pregnancy and Postpartum (7 papers). Robert Riesenberg collaborates with scholars based in United States, Japan and Germany. Robert Riesenberg's co-authors include Stephen Kanes, David R. Rubinow, Jeffrey M. Jonas, Samantha Meltzer‐Brody, Kristina M. Deligiannidis, C. Neill Epperson, Helen Colquhoun, Haihong Li, Abdul J. Sankoh and Christine Clemson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Robert Riesenberg

39 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials

2018 407 citations Samantha Meltzer‐Brody, Helen Colquhoun et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Riesenberg United States	15	621	528	415	410	314	39	1.8k
Alessandro Valchera Italy	29	690 1.1×	772 1.5×	208 0.5×	345 0.8×	111 0.4×	50	2.0k
Maurizio Fava United States	11	370 0.6×	578 1.1×	180 0.4×	735 1.8×	222 0.7×	15	1.8k
Mohammad Haghighi Iran	26	676 1.1×	455 0.9×	145 0.3×	218 0.5×	127 0.4×	86	1.8k
David Christmas United Kingdom	21	444 0.7×	608 1.2×	103 0.2×	591 1.4×	257 0.8×	39	2.3k
Kristina M. Deligiannidis United States	23	543 0.9×	313 0.6×	1.5k 3.6×	372 0.9×	292 0.9×	86	2.5k
J.C. Ballenger United States	19	809 1.3×	846 1.6×	156 0.4×	374 0.9×	441 1.4×	196	2.2k
Olli Kampman Finland	28	487 0.8×	975 1.8×	83 0.2×	380 0.9×	316 1.0×	112	2.1k
Richard Musil Germany	25	494 0.8×	864 1.6×	80 0.2×	302 0.7×	193 0.6×	100	2.0k
John Krystal United States	20	565 0.9×	334 0.6×	208 0.5×	430 1.0×	853 2.7×	34	2.0k
William Pitchot Belgium	22	454 0.7×	332 0.6×	105 0.3×	189 0.5×	266 0.8×	107	1.5k

Countries citing papers authored by Robert Riesenberg

Since Specialization

Citations

This map shows the geographic impact of Robert Riesenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Riesenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Riesenberg more than expected).

Fields of papers citing papers by Robert Riesenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Riesenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Riesenberg. The network helps show where Robert Riesenberg may publish in the future.

Co-authorship network of co-authors of Robert Riesenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Riesenberg. A scholar is included among the top collaborators of Robert Riesenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Riesenberg. Robert Riesenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riesenberg, Robert, et al.. (2023). Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy. The Journal of Clinical Psychiatry. 84(5). 9 indexed citations

Yeung, Paul, Robert Riesenberg, Amelia Orejudos, et al.. (2023). Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study. Journal of Child and Adolescent Psychopharmacology. 33(6). 232–242. 4 indexed citations

Riccobene, Todd, Robert Riesenberg, Paul Yeung, Willie Earley, & Arlene Hankinson. (2022). Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia. Journal of Child and Adolescent Psychopharmacology. 32(8). 434–443. 5 indexed citations

Epperson, C. Neill, David R. Rubinow, Samantha Meltzer‐Brody, et al.. (2022). Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. Journal of Affective Disorders. 320. 353–359. 42 indexed citations

Meltzer‐Brody, Samantha, Helen Colquhoun, Robert Riesenberg, et al.. (2019). Brexanolone Injection in Postpartum Depression: Two Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey. 74(4). 219–220. 1 indexed citations

Gunduz-Bruce, Handan, Christopher Silber, Inder Kaul, et al.. (2019). Trial of SAGE-217 in Patients with Major Depressive Disorder. New England Journal of Medicine. 381(10). 903–911. 161 indexed citations

Mastrandrea, Lucy D., et al.. (2019). Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatric Obesity. 14(5). e12495–e12495. 66 indexed citations

Meltzer‐Brody, Samantha, Helen Colquhoun, Robert Riesenberg, et al.. (2018). Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet. 392(10152). 1058–1070. 407 indexed citations breakdown →

Dogterom, Peter, Robert Riesenberg, Rik de Greef, et al.. (2018). Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Design Development and Therapy. Volume 12. 2677–2693. 6 indexed citations

10.

Meltzer‐Brody, Samantha, Stephen Kanes, Robert Riesenberg, et al.. (2018). S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-In-Class GABAA Receptor Positive Allosteric Modulator for Postpartum Depression. Biological Psychiatry. 83(9). S385–S386. 2 indexed citations

11.

Gunduz-Bruce, Handan, Robert Riesenberg, Abdul J. Sankoh, et al.. (2017). SAGE-217 in subjects with major depressive disorder: efficacy and safety results from open-label Part A of a phase 2A study. European Neuropsychopharmacology. 27. S856–S857. 2 indexed citations

12.

Kanes, Stephen, Helen Colquhoun, Handan Gunduz‐Bruce, et al.. (2017). Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. The Lancet. 390(10093). 480–489. 304 indexed citations

13.

Spyker, Daniel A., Robert Riesenberg, & James V. Cassella. (2015). Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. The Journal of Clinical Pharmacology. 55(9). 985–994. 13 indexed citations

14.

Kwentus, Joseph A., Robert Riesenberg, Michael H. Allen, et al.. (2012). Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine. Bipolar Disorders. 14(1). 31–40. 75 indexed citations

15.

Riesenberg, Robert, et al.. (2012). Self-Reported Sedation Profile of Quetiapine Extended-Release and Quetiapine Immediate-Release During 6-Day Initial Dose Escalation in Bipolar Depression: A Multicenter, Randomized, Double-Blind, Phase IV Study. Clinical Therapeutics. 34(11). 2202–2211. 15 indexed citations

16.

Lesem, Michael D., Tram Tran-Johnson, Robert Riesenberg, et al.. (2011). Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. The British Journal of Psychiatry. 198(1). 51–58. 90 indexed citations

17.

Riesenberg, Robert, et al.. (2011). Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder. Psychopharmacology. 221(4). 601–610. 2 indexed citations

18.

Anderson, Matt S., William D. Hanley, Bo Jin, et al.. (2010). Effect of Raltegravir on the Pharmacokinetics of Methadone. The Journal of Clinical Pharmacology. 50(12). 1461–1466. 8 indexed citations

19.

Riesenberg, Robert, Darcie L. Kurtz, Thomas A. Hardy, et al.. (2006). A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clinical Therapeutics. 28(6). 881–892. 19 indexed citations

20.

March, John S., Joseph Biederman, Robert Wolkow, et al.. (1998). Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder. JAMA. 280(20). 1752–1752. 322 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact